Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients
고형장기 이식 환자의 코로나19 단일클론항체 치료
Article
Published on
Journal: Transplant infectious disease : an official journa [Category] COVID19(2023년), MERS, SARS, 변종, 진단,
Journal: Transplant infectious disease : an official journa [Category] COVID19(2023년), MERS, SARS, 변종, 진단,
[키워드] adverse event
adverse events
age
antibody treatment
bamlanivimab
biopsy
Casirivimab
casirivimab-imdevimab
circulating viral variant
circulating viral variants
Comparator group
confidence
confidence interval
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 symptom
COVID-19 symptoms
deaths
Diabetic
diagnosed with COVID-19
eligible
emergency department
Emergency use authorization
Follow-up
generally mild
high risk
High-risk patients
Hospitalization
Imdevimab
infusion
interval
Intervention
IQR
kidney
kidney transplant
liver
lung
median age
median time
Mild
mild to moderate
Mild to moderate COVID-19
Moderate COVID-19
monoclonal
monoclonal antibodies
monoclonal antibody
nine
occurred
organ
Organ transplant
outcome
Patient
patients
Ratio
receive
recipient
recipients
reduce
rejection
risk
SARS-CoV-2
SARS-CoV-2 spike protein
severe coronavirus disease
single-center
Solid
solid organ
solid organ transplant
SOT
Spike protein
statistically significant
study period
the SARS-CoV-2
therapy
Transplant
treated
Treatment
two patients
Viral
Viral variants
[DOI] 10.1111/tid.13759 PMC 바로가기 [Article Type] Article
[DOI] 10.1111/tid.13759 PMC 바로가기 [Article Type] Article